Clinician’s Brief podcast revisits practical OA pain management

Version 2

Clinician’s Brief is spotlighting osteoarthritis pain management in a new partner podcast episode with Dr. Robin Downing, a longtime veterinary pain specialist, in a conversation sponsored by PRN Pharmacal. The episode description says the discussion centers on Downing’s clinical approach to OA patients, including how she evaluates inflammation, manages chronic pain and sensitization, and integrates multiple therapeutic options into care plans. (podcasts.apple.com)

The topic is timely because osteoarthritis remains one of the most common chronic pain conditions seen in companion animal practice, yet it’s still underrecognized, especially in earlier stages. The 2022 AAHA Pain Management Guidelines for Dogs and Cats explicitly call for a practical, logical framework for both acute and chronic pain, with chronic musculoskeletal pain, especially OA, treated as an area where regular reassessment and multimodal planning are essential. Those guidelines also highlight validated client questionnaires such as the Canine Brief Pain Inventory and LOAD as useful tools for monitoring response over time. (aaha.org)

That broader context helps explain why a “practical advice” format matters. Downing has consistently advocated for multimodal pain management, not just analgesic prescribing. In prior commentary, she has emphasized that patients need plans that combine pain control with physical medicine and rehabilitation, and that pain relief should come before pushing rehab exercises in chronic OA cases. AAHA educational materials and other veterinary coverage echo that same theme, pointing clinicians toward combinations of pharmacologic therapy, rehabilitation, and home-environment changes rather than a one-drug strategy. (aaha.org)

The pharmacology backdrop has also shifted. NSAIDs remain central to OA management, and recent reviews still describe them as the cornerstone for controlling OA pain and inflammation. At the same time, anti-NGF monoclonal antibodies have become a major part of the conversation. In March 2025, Zoetis announced results from a clinical trial reporting that Librela (bedinvetmab) provided pain relief equivalent to meloxicam in dogs with OA, positioning both as first-line options within guideline-based care. That doesn’t replace the need for individualized case selection, but it does show how quickly the therapeutic menu is changing. (news.zoetis.com)

Industry and expert commentary around OA care increasingly converges on the same point: success depends on recognizing that chronic pain is bigger than joint inflammation alone. Downing’s previous interviews and educational appearances have stressed the risks of undertreating pain, missing alternative diagnoses, and overlooking modalities such as rehabilitation, acupuncture, massage, and other supportive interventions when appropriate. That perspective is particularly relevant in general practice, where subtle mobility changes may be normalized by pet parents until function has already declined. (dvm360.com)

Why it matters: For veterinary teams, this podcast is useful less as breaking news and more as a clinical signal about where OA management is heading. The standard of discussion is moving toward earlier detection, formal pain scoring, longitudinal monitoring, and layered treatment plans tailored to the patient and household. For practices, that can mean more deliberate use of screening tools, clearer conversations with pet parents about chronic pain and mobility, and better coordination between prescribing, follow-up, rehab, nutrition, and home-care recommendations. (jaaha.kglmeridian.com)

It also matters commercially and operationally. Sponsored educational content from companies tied to pain and mobility products reflects sustained industry attention on OA as both a major welfare issue and a long-term practice touchpoint. That can create opportunities for better care, but it also means clinicians need to separate broad evidence-based principles from product-specific promotion and keep monitoring requirements, contraindications, and patient selection front and center. The AAHA guidelines note that they are guidance, not a standard of care, which leaves room for clinical judgment but also puts more weight on thoughtful case-by-case decision-making. (podcasts.apple.com)

What to watch: The next phase of OA coverage will likely focus on how general practices operationalize multimodal care, especially around first-line drug selection, rehab access, and long-term monitoring as newer therapies gain traction. (news.zoetis.com)